Myriad Genetics Inc MYGN:NASDAQ

Last Price$14.44Cboe Real-Time Last Sale as of 10:17AM ET 5/29/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.03(0.21%)
Bid (Size)$14.43 (300)
Ask (Size)$14.46 (2)
Day Low / High$14.28 - 14.52
Volume46.4 K
 

View Biotechnology IndustryPeer Comparison as of 05/29/2020

 

Myriad Genetics Inc ( NASDAQ )

Price: $14.44
Change: +0.03 (0.21%)
Volume: 46.4 K
10:17AM ET 5/29/2020
 
 

Rocket Pharmaceuticals Inc ( NASDAQ )

Price: $18.60
Change: -0.28 (1.48%)
Volume: 12.7 K
10:08AM ET 5/29/2020
 
 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $16.42
Change: -0.58 (3.41%)
Volume: 54.8 K
10:17AM ET 5/29/2020
 
 

Sorrento Therapeutics Inc ( NASDAQ )

Price: $4.98
Change: +0.03 (0.61%)
Volume: 2.6 M
10:16AM ET 5/29/2020
 
 

Enanta Pharmaceuticals Inc ( NASDAQ )

Price: $49.96
Change: -1.64 (3.18%)
Volume: 25.5 K
10:17AM ET 5/29/2020
 

Read more news Recent News

Cerecor, Myriad Genetics' Study Suggests LIGHT Levels 'Highly Correlated' With COVID-19 ARDS, Death
11:38AM ET 5/26/2020 MT Newswires

Biopharmaceutical companies Cerecor (CERC) and Myriad Genetics (MYGN) said Tuesday results of their biomarker study suggest that levels of the novel...

AstraZeneca, Merck Get FDA Nod for Lynparza to Treat Prostate Cancer
1:20PM ET 5/20/2020 MT Newswires

AstraZeneca (AZN) and Merck (MRK) said on Wednesday the US Food and Drug Administration (FDA) has approved Lynparza for the treatment of certain metastatic...

Myriad Genetics' BRACAnalysis Test Gets FDA Approval As Companion Diagnostic For Lynparza
7:27AM ET 5/20/2020 MT Newswires

Myriad Genetics (MYGN) said Wednesday the US Food and Drug Administration (FDA) has approved its BRACAnalysis CDx test as a companion diagnostic for...

Myriad Genetics' 2020, 2021, and Q4 Earnings Estimates Reduced
6:45AM ET 5/16/2020 MT Newswires

Myriad Genetics Inc's (NASDAQ:MYGN, Recent Price: 14.73) earnings projections for Q4 ending June 30, 2020, and the expectations for 2020 and 2021 have been...

Company Profile

Business DescriptionMyriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT. View company web site for more details
Address320 Wakara Way
Salt Lake City, Utah 84108
Phone+1.801.584.3600
Number of Employees2,400
Recent SEC Filing05/28/20208-K
President, Chief Executive & Financial OfficerR. Bryan Riggsbee
Executive Vice President-International OperationsGary A. King
Chief Information OfficerRobert Gardner Harrison
Chief Scientific OfficerJerry S. Lanchbury

Company Highlights

Price Open$14.51
Previous Close$14.41
52 Week Range$9.24 - 48.40
Market Capitalization$1.1 B
Shares Outstanding74.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/11/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.91
Beta vs. S&P 500N/A
Revenue$772.6 M
Net Profit Margin-19.49%
Return on Equity-14.10%

Analyst Ratings as of 05/17/2020

Buy
1
Overweight
1
Hold
4
Underweight
1
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset